Cabaletta Bio Inc (CABA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cabaletta Bio Inc (CABA) has a cash flow conversion efficiency ratio of -0.412x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-42.56 Million) by net assets ($103.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cabaletta Bio Inc balance sheet independence to measure how much of total assets are equity-financed.
Cabaletta Bio Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Cabaletta Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore CABA long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cabaletta Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cabaletta Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gallant Precision Machining Co Ltd
TWO:5443
|
0.031x |
|
Aerostar Bacau
RO:ARS
|
N/A |
|
Prothena Corporation plc
NASDAQ:PRTA
|
-0.138x |
|
Magnera Corp placeholder
NYSE:MAGN
|
0.084x |
|
Weave Communications Inc
NYSE:WEAV
|
0.077x |
|
Jiangsu Baoli Asphalt
SHE:300135
|
-0.020x |
|
IndoStar Capital Finance Limited
NSE:INDOSTAR
|
-0.064x |
|
Concord International Securities Co Ltd
TWO:5864
|
-0.119x |
Annual Cash Flow Conversion Efficiency for Cabaletta Bio Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Cabaletta Bio Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see CABA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $112.05 Million | $-131.08 Million | -1.170x | -102.00% |
| 2024-12-31 | $152.34 Million | $-88.22 Million | -0.579x | -155.45% |
| 2023-12-31 | $236.20 Million | $-53.55 Million | -0.227x | +48.91% |
| 2022-12-31 | $104.52 Million | $-46.38 Million | -0.444x | -53.46% |
| 2021-12-31 | $117.96 Million | $-34.11 Million | -0.289x | -18.33% |
| 2020-12-31 | $109.54 Million | $-26.77 Million | -0.244x | -110.67% |
| 2019-12-31 | $138.32 Million | $-16.05 Million | -0.116x | -126.60% |
| 2018-12-31 | $-10.69 Million | $-4.66 Million | 0.436x | -97.67% |
| 2017-12-31 | $-249.00K | $-4.66 Million | 18.719x | -- |
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase synd… Read more